Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference [Yahoo! Finance]
Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) [Yahoo! Finance]
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
Seres Therapeutics, Inc. (NASDAQ: MCRB) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.